Skip to main content

CD86 KO cell line available to order. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9; X = 1 bp insertion; Frameshift: 99%.

Be the first to review this product! Submit a review

Images

Western blot - Human CD86 knockout Raji cell line (AB273858), expandable thumbnail
  • Western blot - Human CD86 knockout Raji cell line (AB273858), expandable thumbnail
  • Next Generation Sequencing - Human CD86 knockout Raji cell line (AB273858), expandable thumbnail
  • Western blot - Human CD86 knockout Raji cell line (AB273858), expandable thumbnail
  • Next Generation Sequencing - Human CD86 knockout Raji cell line (AB273858), expandable thumbnail

Key facts

Cell type
Raji
Species or organism
Human
Tissue
Lymphatic
Form
Liquid
Knockout validation
Next Generation Sequencing, Western blot
Mutation description
Knockout achieved by CRISPR/Cas9; X = 1 bp insertion; Frameshift: 99%

Alternative names

Activation B7-2 antigen, Activation B7-2 antigen 3, B-lymphocyte activation antigen B7-2, B-lymphocyte activation antigen B7-2 2, B7, B7-2, B7.2, B70, B72 antigen, BU63, CD28 antigen ligand 2, CD28 antigen ligand 2 2, CD28LG2, CD86 antigen, CD86 antigen (CD28 antigen ligand 2, B7-2 antigen), CD86 antigen (CD28 antigen ligand 2, B7-2 antigen) 1, 2, CD86 molecule, CD86_HUMAN, CLS1, CTLA-4 counter-receptor B7.2, CTLA-4 counter-receptor B7.2 2, CTLA-4 counter-receptor B7.2 2, 3, Cd28l2, ETC-1, Early T-cell costimulatory molecule 1, FUN-1, LAB72, Ly-58, MB7, MB7-2, MGC34413, Membrane glycoprotein, T lymphocyte activation antigen CD86 precursor, T-lymphocyte activation antigen CD86, TS/A-2

Recommended products

CD86 KO cell line available to order. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9; X = 1 bp insertion; Frameshift: 99%.

Key facts

Cell type
Raji
Form
Liquid
Mutation description
Knockout achieved by CRISPR/Cas9; X = 1 bp insertion; Frameshift: 99%
Disease
Lymphoma
Concentration
Loading...

Properties

Gene name
CD86
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing, Western blot

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Suspension
Gender
Male

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water for bath approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method. Based on cell count, seed cells in an appropriate cell culture flask at a density of 4x105 - 5x105 cells/mL(for initial passages it is recomended to culture the cells in the higher range of recomended seeding density). Seeding density is given as a guide only and should be scaled to align with individual lab schedules.
4. Incubate the culture at 37°C incubator with 5% CO2. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 4x105 cells/mL is recommended.
  • A maximum of 3x106 viable cells/mL is obtainable.
Culture medium
RPMI + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type Raji cell line (ab271145). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

CD86 also known as B7-2 is a protein involved in the regulation of the immune response. It has an approximate mass of 70 kDa and is expressed on antigen-presenting cells like dendritic cells monocytes and macrophages. Notably CD86 is present on macrophages including those in tissues such as skin and lymphoid organs. Expressed on these cells CD86 serves as a vital mediator in the co-stimulatory signals necessary for T cell activation and survival.

Biological function summary

CD86 plays a significant role in the immune system by providing secondary signals for T cell activation and differentiation. It is a part of the B7 protein family and forms a complex with CD28 and CTLA-4 on T cells. When CD86 binds to CD28 it sends positive co-stimulatory signals which promote T cell proliferation and cytokine production. On the other hand interaction with CTLA-4 transmits an inhibitory signal which reduces immune response. This dual interaction helps to balance immune activation and tolerance.

Pathways

CD86 takes part in important immune-related signaling pathways particularly the T cell receptor signaling pathway and the PI3K-Akt signaling pathway. Both pathways are fundamental for initiating immune responses. CD86's interaction with CD28 activates downstream signaling cascades including PI3K-Akt which is important for cell survival and growth. Additionally CD86 collaborates with other proteins such as CD80 another co-stimulatory molecule to amplify T cell activation within these pathways.

Associated diseases and disorders

CD86 is associated with autoimmune diseases and transplant rejection. In autoimmune diseases like rheumatoid arthritis the overexpression or dysregulation of CD86 can lead to excessive T cell activation causing immune system attacks on the body's own tissues. Similarly in transplant rejection CD86 may contribute by enhancing immune response against transplanted organs. The engagement between CD86 and CD28 is a critical factor in these conditions and therapies targeting this interaction are under exploration to mitigate the immune response.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

5 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com